SCHEMBL12388704

SCHEMBL12388704

CCOC(=O)c1[nH]c2cc(F)c3ccoc3c2c1-c1ccc[nH]c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.37
▸ HPGD P15428 3/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ XBP1 P17861 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ MAPT P10636 6/20 0.36
▸ GAA P10253 2/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ MAP3K5 Q99683 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ NPC1 O15118 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ TP53 P04637 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12388706 0.86 CYP2C8 (0.33) ALDH1A1HPGDKMT2AMEN1HSD17B10
SCHEMBL12388702 0.81 KCNA3 (0.38) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL12388700 0.79 KDM4E (0.41) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL12388829 0.74 CYP2C8 (0.38) ALDH1A1HPGDMAPTKMT2AMEN1
SCHEMBL12665723 0.74 ALDH1A1 (0.50) ALDH1A1HPGDCYP1A2XBP1CYP2C19
SCHEMBL13395200 0.73 CYP2C8 (0.39) ALDH1A1MAPTGAAKMT2ANPSR1
SCHEMBL13395187 0.72 CYP2C8 (0.40) ALDH1A1MAPTKMT2AMEN1
SCHEMBL12388694 0.72 KDM4E (0.46) ALDH1A1HPGDMAPTGAAKMT2A
SCHEMBL12388327 0.71 CYP2C8 (0.41) ALDH1A1HPGDMAPTKMT2ANPSR1
SCHEMBL12389057 0.70 CYP2C8 (0.40) ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303893-B1 TRICYCLIC INDOLE DERIVATIVES MERCK SHARP & DOHME (US) 2016-12-07 — — EP disclosed
EP-2064180-B1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS MERCK SHARP & DOHME (US) 2016-07-13 — — EP disclosed
US-8901139-B2 Tricyclic indole derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-12-02 — — US disclosed
US-8901139-B2 Tricyclic indole derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2014-12-02 — — US disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-20110189127-A1 TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2011-08-04 — — US disclosed
US-20110189127-A1 TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2011-08-04 — — US disclosed
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-05-05 — — US disclosed
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-05-05 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
WO-2008082484-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110104109-A1 TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS IDO1, IDO2, ZC3HAV1 ALDH1A1 2482/4885HPGD 3175/4885CYP1A2 1184/4885
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L ALDH1A1 248/4885HPGD 1986/4885CYP1A2 78/4885
US-20110189127-A1 TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, TPH1 ALDH1A1 1741/4885HPGD 1239/4885CYP1A2 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback